Share Price and Basic Stock Data
Last Updated: January 21, 2026, 5:07 pm
| PEG Ratio | 3.55 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
CCL Products (India) Ltd operates within the Plantations sector, focusing on tea and coffee, and has demonstrated robust revenue growth in recent periods. The company’s sales rose significantly from ₹1,462 Cr in FY 2022 to ₹2,071 Cr in FY 2023, reflecting a year-on-year increase of approximately 42%. The upward trend is expected to continue, with sales projected at ₹2,654 Cr for FY 2024 and ₹3,106 Cr for FY 2025, marking a compound annual growth rate (CAGR) of around 27% over this two-year period. Quarterly trends also support this growth narrative, with sales increasing from ₹507 Cr in September 2022 to ₹608 Cr in September 2023. This trajectory suggests a solid market positioning, aided by a growing global demand for coffee and coffee-related products, which is critical for CCL’s expansion plans. The company has cultivated a diverse product portfolio, catering to various consumer preferences, which further enhances its revenue-generating capabilities.
Profitability and Efficiency Metrics
CCL Products has exhibited commendable profitability metrics, with a reported net profit of ₹338 Cr for FY 2025, reflecting a net profit margin of 9.99%. The operating profit margin (OPM) stood at 18% for FY 2025, indicating effective cost management despite rising operational expenses. The company’s interest coverage ratio (ICR) of 4.99x signifies a healthy ability to meet interest obligations, while the return on equity (ROE) of 17% indicates efficient use of shareholder funds. However, the return on capital employed (ROCE) declined to 13.1% in FY 2025, suggesting a need for improved capital efficiency. The cash conversion cycle (CCC) of 246 days, while manageable, highlights potential inefficiencies in inventory management and receivables collection. Notably, the company’s expenses surged from ₹1,131 Cr in FY 2022 to ₹2,208 Cr in FY 2024, necessitating a closer examination of cost control measures to sustain profitability.
Balance Sheet Strength and Financial Ratios
CCL Products demonstrates a solid balance sheet, with total assets reported at ₹4,241 Cr for FY 2025, supported by reserves of ₹2,060 Cr. The company’s borrowings stood at ₹1,628 Cr, yielding a debt-to-equity ratio of 0.92, which is within a manageable range compared to industry standards. The current ratio of 1.28 indicates adequate short-term liquidity, while the quick ratio of 0.63 reflects potential liquidity challenges in meeting immediate obligations. The book value per share increased to ₹147.33 in FY 2025, providing a strong foundation for future growth. Additionally, the enterprise value (EV) of ₹9,123.03 Cr highlights the market’s valuation of the company relative to its operational performance. However, the increasing interest expense, which rose to ₹113 Cr in FY 2025, necessitates vigilant financial management to prevent strain on profitability.
Shareholding Pattern and Investor Confidence
The shareholding structure of CCL Products indicates a well-distributed ownership model, with promoters holding 46.11% as of September 2025. This stake reflects a commitment to the company’s long-term vision. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), hold 10.52% and 21.83% respectively, showcasing a healthy level of institutional confidence. The number of shareholders increased to 55,690, indicating growing interest from retail investors. However, the public shareholding decreased to 21.29%, which may raise concerns about liquidity and market participation. The consistent presence of DIIs suggests confidence in the company’s operational and financial strategies, while the gradual increase in FII participation from 7.59% in December 2022 to 10.52% in September 2025 indicates positive sentiment from foreign investors.
Outlook, Risks, and Final Insight
Looking ahead, CCL Products is well-positioned to capitalize on the growing global demand for coffee, supported by its strong financial metrics and operational efficiencies. However, risks such as rising raw material costs, potential supply chain disruptions, and intense competition in the coffee industry could impact profitability. Additionally, the company must address its cash conversion cycle to improve working capital management. Should CCL Products successfully navigate these challenges, it could enhance shareholder value significantly. Conversely, persistent inefficiencies and external market pressures could hinder growth. The overall outlook remains cautiously optimistic, contingent on the company’s ability to adapt to market dynamics while maintaining its competitive edge in the coffee and tea sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Goodricke Group Ltd | 333 Cr. | 154 | 275/152 | 149 | 0.00 % | 3.22 % | 2.86 % | 10.0 | |
| Diana Tea Company Ltd | 40.8 Cr. | 27.2 | 42.0/23.3 | 47.3 | 0.00 % | 1.40 % | 7.16 % | 5.00 | |
| Bengal Tea & Fabrics Ltd | 137 Cr. | 152 | 185/126 | 26.7 | 223 | 0.99 % | 5.22 % | 55.3 % | 10.0 |
| Bansisons Tea Industries Ltd | 10.0 Cr. | 15.9 | 15.9/5.60 | 9.42 | 0.00 % | 1.01 % | 1.01 % | 10.0 | |
| B&A Ltd | 117 Cr. | 377 | 685/354 | 12.5 | 528 | 0.00 % | 8.96 % | 6.02 % | 10.0 |
| Industry Average | 8,803.41 Cr | 383.92 | 65.90 | 265.00 | 0.44% | 7.88% | 16.74% | 7.00 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 507 | 535 | 520 | 655 | 608 | 664 | 727 | 773 | 738 | 758 | 836 | 1,056 | 1,127 |
| Expenses | 409 | 435 | 407 | 549 | 498 | 554 | 609 | 643 | 601 | 634 | 673 | 897 | 930 |
| Operating Profit | 98 | 101 | 113 | 106 | 110 | 111 | 118 | 130 | 137 | 124 | 163 | 159 | 197 |
| OPM % | 19% | 19% | 22% | 16% | 18% | 17% | 16% | 17% | 19% | 16% | 20% | 15% | 18% |
| Other Income | 0 | 0 | 2 | 0 | 1 | 1 | 4 | 1 | 1 | 3 | 4 | 2 | 1 |
| Interest | 7 | 11 | 11 | 15 | 18 | 23 | 21 | 21 | 27 | 31 | 34 | 34 | 33 |
| Depreciation | 17 | 19 | 10 | 22 | 23 | 22 | 31 | 23 | 24 | 25 | 27 | 34 | 39 |
| Profit before tax | 73 | 71 | 95 | 69 | 70 | 67 | 70 | 87 | 87 | 72 | 106 | 94 | 127 |
| Tax % | 21% | -4% | 10% | 13% | 13% | 5% | 7% | 18% | 15% | 12% | 4% | 23% | 21% |
| Net Profit | 58 | 73 | 85 | 61 | 61 | 63 | 65 | 71 | 74 | 63 | 102 | 72 | 101 |
| EPS in Rs | 4.34 | 5.49 | 6.41 | 4.56 | 4.57 | 4.76 | 4.88 | 5.35 | 5.54 | 4.72 | 7.63 | 5.43 | 7.55 |
Last Updated: January 2, 2026, 3:32 am
Below is a detailed analysis of the quarterly data for CCL Products (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,127.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,056.00 Cr. (Jun 2025) to 1,127.00 Cr., marking an increase of 71.00 Cr..
- For Expenses, as of Sep 2025, the value is 930.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 897.00 Cr. (Jun 2025) to 930.00 Cr., marking an increase of 33.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 197.00 Cr.. The value appears strong and on an upward trend. It has increased from 159.00 Cr. (Jun 2025) to 197.00 Cr., marking an increase of 38.00 Cr..
- For OPM %, as of Sep 2025, the value is 18.00%. The value appears strong and on an upward trend. It has increased from 15.00% (Jun 2025) to 18.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Jun 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 33.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 34.00 Cr. (Jun 2025) to 33.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 34.00 Cr. (Jun 2025) to 39.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 127.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Jun 2025) to 127.00 Cr., marking an increase of 33.00 Cr..
- For Tax %, as of Sep 2025, the value is 21.00%. The value appears to be improving (decreasing) as expected. It has decreased from 23.00% (Jun 2025) to 21.00%, marking a decrease of 2.00%.
- For Net Profit, as of Sep 2025, the value is 101.00 Cr.. The value appears strong and on an upward trend. It has increased from 72.00 Cr. (Jun 2025) to 101.00 Cr., marking an increase of 29.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 7.55. The value appears strong and on an upward trend. It has increased from 5.43 (Jun 2025) to 7.55, marking an increase of 2.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:31 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 717 | 881 | 932 | 976 | 1,138 | 1,081 | 1,139 | 1,242 | 1,462 | 2,071 | 2,654 | 3,106 | 3,777 |
| Expenses | 574 | 709 | 727 | 744 | 899 | 836 | 853 | 945 | 1,131 | 1,671 | 2,208 | 2,551 | 3,133 |
| Operating Profit | 143 | 171 | 205 | 232 | 239 | 245 | 286 | 298 | 331 | 400 | 445 | 555 | 644 |
| OPM % | 20% | 19% | 22% | 24% | 21% | 23% | 25% | 24% | 23% | 19% | 17% | 18% | 17% |
| Other Income | 3 | 3 | 1 | 1 | 5 | 3 | 4 | 3 | 4 | 3 | 6 | 8 | 10 |
| Interest | 17 | 14 | 11 | 11 | 8 | 8 | 18 | 17 | 16 | 34 | 78 | 113 | 131 |
| Depreciation | 29 | 27 | 28 | 33 | 34 | 32 | 47 | 49 | 57 | 64 | 98 | 98 | 124 |
| Profit before tax | 100 | 134 | 167 | 189 | 202 | 209 | 225 | 235 | 261 | 305 | 276 | 352 | 399 |
| Tax % | 35% | 30% | 27% | 29% | 27% | 26% | 26% | 22% | 22% | 7% | 9% | 12% | |
| Net Profit | 64 | 94 | 122 | 135 | 148 | 155 | 166 | 182 | 204 | 284 | 250 | 310 | 338 |
| EPS in Rs | 4.84 | 7.06 | 9.18 | 10.12 | 11.14 | 11.64 | 12.47 | 13.70 | 15.36 | 21.35 | 18.73 | 23.24 | 25.33 |
| Dividend Payout % | 25% | 21% | 27% | 25% | 22% | 30% | 40% | 29% | 33% | 21% | 24% | 22% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 46.88% | 29.79% | 10.66% | 9.63% | 4.73% | 7.10% | 9.64% | 12.09% | 39.22% | -11.97% | 24.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -17.09% | -19.13% | -1.03% | -4.90% | 2.37% | 2.54% | 2.45% | 27.13% | -51.19% | 35.97% |
CCL Products (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 22% |
| 3 Years: | 29% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 13% |
| 3 Years: | 15% |
| TTM: | 19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 29% |
| 3 Years: | 23% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 18% |
| 3 Years: | 18% |
| Last Year: | 17% |
Last Updated: September 5, 2025, 1:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:05 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 |
| Reserves | 326 | 395 | 483 | 602 | 713 | 812 | 902 | 1,061 | 1,224 | 1,471 | 1,647 | 1,941 | 2,060 |
| Borrowings | 292 | 229 | 210 | 142 | 311 | 416 | 469 | 559 | 655 | 920 | 1,622 | 1,815 | 1,628 |
| Other Liabilities | 80 | 111 | 81 | 78 | 83 | 166 | 112 | 142 | 164 | 180 | 240 | 459 | 574 |
| Total Liabilities | 725 | 762 | 801 | 848 | 1,134 | 1,422 | 1,509 | 1,788 | 2,070 | 2,597 | 3,536 | 4,241 | 4,288 |
| Fixed Assets | 361 | 340 | 417 | 393 | 371 | 383 | 724 | 798 | 882 | 1,257 | 1,252 | 1,622 | 2,027 |
| CWIP | 39 | 53 | 0 | 0 | 226 | 424 | 100 | 149 | 160 | 54 | 501 | 450 | 18 |
| Investments | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 324 | 367 | 382 | 453 | 535 | 613 | 684 | 841 | 1,028 | 1,286 | 1,783 | 2,169 | 2,244 |
| Total Assets | 725 | 762 | 801 | 848 | 1,134 | 1,422 | 1,509 | 1,788 | 2,070 | 2,597 | 3,536 | 4,241 | 4,288 |
Below is a detailed analysis of the balance sheet data for CCL Products (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 27.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 27.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,060.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,941.00 Cr. (Mar 2025) to 2,060.00 Cr., marking an increase of 119.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,628.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1,815.00 Cr. (Mar 2025) to 1,628.00 Cr., marking a decrease of 187.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 574.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 459.00 Cr. (Mar 2025) to 574.00 Cr., marking an increase of 115.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 4,288.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,241.00 Cr. (Mar 2025) to 4,288.00 Cr., marking an increase of 47.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2,027.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,622.00 Cr. (Mar 2025) to 2,027.00 Cr., marking an increase of 405.00 Cr..
- For CWIP, as of Sep 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 450.00 Cr. (Mar 2025) to 18.00 Cr., marking a decrease of 432.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,244.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,169.00 Cr. (Mar 2025) to 2,244.00 Cr., marking an increase of 75.00 Cr..
- For Total Assets, as of Sep 2025, the value is 4,288.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,241.00 Cr. (Mar 2025) to 4,288.00 Cr., marking an increase of 47.00 Cr..
Notably, the Reserves (2,060.00 Cr.) exceed the Borrowings (1,628.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -149.00 | -58.00 | -5.00 | 90.00 | -72.00 | -171.00 | -183.00 | -261.00 | -324.00 | -520.00 | 444.00 | 554.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54 | 47 | 50 | 61 | 58 | 79 | 86 | 88 | 80 | 78 | 68 | 81 |
| Inventory Days | 118 | 116 | 99 | 121 | 97 | 123 | 170 | 198 | 262 | 187 | 185 | 208 |
| Days Payable | 18 | 29 | 8 | 8 | 5 | 35 | 16 | 13 | 23 | 24 | 23 | 44 |
| Cash Conversion Cycle | 155 | 134 | 142 | 174 | 150 | 168 | 240 | 272 | 319 | 241 | 230 | 246 |
| Working Capital Days | 36 | 45 | 37 | 81 | 89 | 43 | 103 | 59 | 77 | 58 | 40 | 42 |
| ROCE % | 19% | 23% | 26% | 27% | 23% | 19% | 18% | 17% | 16% | 16% | 12% | 13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Axis Small Cap Fund | 6,893,602 | 2.6 | 695.29 | 6,944,251 | 2025-12-15 00:22:23 | -0.73% |
| Franklin India Small Cap Fund | 3,010,279 | 2.24 | 303.62 | 3,260,279 | 2025-12-15 00:22:23 | -7.67% |
| SBI MNC Fund | 2,410,387 | 4.05 | 243.11 | 2,500,000 | 2025-12-15 00:22:23 | -3.58% |
| HSBC Small Cap Fund | 2,071,654 | 1.29 | 208.95 | N/A | N/A | N/A |
| Parag Parikh ELSS Tax Saver Fund | 1,401,976 | 2.41 | 141.4 | N/A | N/A | N/A |
| HSBC Value Fund | 1,380,800 | 0.96 | 139.27 | N/A | N/A | N/A |
| Aditya Birla Sun Life Small Cap Fund | 1,078,825 | 2.16 | 108.81 | N/A | N/A | N/A |
| Canara Robeco ELSS Tax Saver Fund | 846,204 | 0.94 | 85.35 | 1,009,157 | 2025-12-15 00:22:23 | -16.15% |
| PGIM India Small Cap Fund | 475,850 | 3 | 47.99 | N/A | N/A | N/A |
| Axis Multicap Fund | 466,913 | 0.51 | 47.09 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 23.31 | 18.80 | 20.21 | 15.36 | 13.70 |
| Diluted EPS (Rs.) | 23.26 | 18.76 | 20.21 | 15.36 | 13.70 |
| Cash EPS (Rs.) | 30.61 | 26.14 | 25.00 | 19.68 | 17.42 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 147.33 | 125.82 | 111.42 | 94.02 | 81.73 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 147.33 | 125.82 | 111.42 | 94.02 | 81.73 |
| Revenue From Operations / Share (Rs.) | 232.59 | 199.48 | 155.70 | 109.90 | 93.40 |
| PBDIT / Share (Rs.) | 42.20 | 33.95 | 30.30 | 25.19 | 22.64 |
| PBIT / Share (Rs.) | 34.83 | 26.61 | 25.51 | 20.87 | 18.92 |
| PBT / Share (Rs.) | 26.38 | 20.77 | 22.93 | 19.65 | 17.65 |
| Net Profit / Share (Rs.) | 23.24 | 18.80 | 20.21 | 15.36 | 13.70 |
| NP After MI And SOA / Share (Rs.) | 23.24 | 18.80 | 20.21 | 15.36 | 13.70 |
| PBDIT Margin (%) | 18.14 | 17.01 | 19.46 | 22.92 | 24.23 |
| PBIT Margin (%) | 14.97 | 13.33 | 16.38 | 18.99 | 20.26 |
| PBT Margin (%) | 11.34 | 10.40 | 14.72 | 17.87 | 18.89 |
| Net Profit Margin (%) | 9.99 | 9.42 | 12.98 | 13.97 | 14.66 |
| NP After MI And SOA Margin (%) | 9.99 | 9.42 | 12.98 | 13.97 | 14.66 |
| Return on Networth / Equity (%) | 15.77 | 14.94 | 18.14 | 16.33 | 16.76 |
| Return on Capital Employeed (%) | 17.85 | 15.67 | 19.27 | 19.28 | 19.07 |
| Return On Assets (%) | 7.31 | 7.07 | 10.35 | 9.87 | 10.19 |
| Long Term Debt / Equity (X) | 0.28 | 0.30 | 0.13 | 0.08 | 0.16 |
| Total Debt / Equity (X) | 0.92 | 0.96 | 0.61 | 0.44 | 0.43 |
| Asset Turnover Ratio (%) | 0.79 | 0.86 | 0.68 | 0.54 | 0.53 |
| Current Ratio (X) | 1.28 | 1.36 | 1.49 | 1.57 | 1.69 |
| Quick Ratio (X) | 0.63 | 0.74 | 0.79 | 0.74 | 1.01 |
| Inventory Turnover Ratio (X) | 3.37 | 2.38 | 1.57 | 1.35 | 1.35 |
| Dividend Payout Ratio (NP) (%) | 8.60 | 26.59 | 24.73 | 32.54 | 14.59 |
| Dividend Payout Ratio (CP) (%) | 6.53 | 19.12 | 19.99 | 25.40 | 11.48 |
| Earning Retention Ratio (%) | 91.40 | 73.41 | 75.27 | 67.46 | 85.41 |
| Cash Earning Retention Ratio (%) | 93.47 | 80.88 | 80.01 | 74.60 | 88.52 |
| Interest Coverage Ratio (X) | 4.99 | 5.81 | 11.72 | 20.49 | 17.76 |
| Interest Coverage Ratio (Post Tax) (X) | 3.75 | 4.22 | 8.82 | 13.49 | 11.75 |
| Enterprise Value (Cr.) | 9123.03 | 9248.47 | 8386.00 | 5873.65 | 3469.07 |
| EV / Net Operating Revenue (X) | 2.94 | 3.49 | 4.05 | 4.02 | 2.79 |
| EV / EBITDA (X) | 16.19 | 20.48 | 20.80 | 17.53 | 11.52 |
| MarketCap / Net Operating Revenue (X) | 2.39 | 2.94 | 3.65 | 3.67 | 2.51 |
| Retention Ratios (%) | 91.39 | 73.40 | 75.26 | 67.45 | 85.40 |
| Price / BV (X) | 3.77 | 4.66 | 5.10 | 4.29 | 2.86 |
| Price / Net Operating Revenue (X) | 2.39 | 2.94 | 3.65 | 3.67 | 2.51 |
| EarningsYield | 0.04 | 0.03 | 0.03 | 0.03 | 0.05 |
After reviewing the key financial ratios for CCL Products (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 23.31. This value is within the healthy range. It has increased from 18.80 (Mar 24) to 23.31, marking an increase of 4.51.
- For Diluted EPS (Rs.), as of Mar 25, the value is 23.26. This value is within the healthy range. It has increased from 18.76 (Mar 24) to 23.26, marking an increase of 4.50.
- For Cash EPS (Rs.), as of Mar 25, the value is 30.61. This value is within the healthy range. It has increased from 26.14 (Mar 24) to 30.61, marking an increase of 4.47.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 147.33. It has increased from 125.82 (Mar 24) to 147.33, marking an increase of 21.51.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 147.33. It has increased from 125.82 (Mar 24) to 147.33, marking an increase of 21.51.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 232.59. It has increased from 199.48 (Mar 24) to 232.59, marking an increase of 33.11.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 42.20. This value is within the healthy range. It has increased from 33.95 (Mar 24) to 42.20, marking an increase of 8.25.
- For PBIT / Share (Rs.), as of Mar 25, the value is 34.83. This value is within the healthy range. It has increased from 26.61 (Mar 24) to 34.83, marking an increase of 8.22.
- For PBT / Share (Rs.), as of Mar 25, the value is 26.38. This value is within the healthy range. It has increased from 20.77 (Mar 24) to 26.38, marking an increase of 5.61.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 23.24. This value is within the healthy range. It has increased from 18.80 (Mar 24) to 23.24, marking an increase of 4.44.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 23.24. This value is within the healthy range. It has increased from 18.80 (Mar 24) to 23.24, marking an increase of 4.44.
- For PBDIT Margin (%), as of Mar 25, the value is 18.14. This value is within the healthy range. It has increased from 17.01 (Mar 24) to 18.14, marking an increase of 1.13.
- For PBIT Margin (%), as of Mar 25, the value is 14.97. This value is within the healthy range. It has increased from 13.33 (Mar 24) to 14.97, marking an increase of 1.64.
- For PBT Margin (%), as of Mar 25, the value is 11.34. This value is within the healthy range. It has increased from 10.40 (Mar 24) to 11.34, marking an increase of 0.94.
- For Net Profit Margin (%), as of Mar 25, the value is 9.99. This value is within the healthy range. It has increased from 9.42 (Mar 24) to 9.99, marking an increase of 0.57.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.99. This value is within the healthy range. It has increased from 9.42 (Mar 24) to 9.99, marking an increase of 0.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.77. This value is within the healthy range. It has increased from 14.94 (Mar 24) to 15.77, marking an increase of 0.83.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.85. This value is within the healthy range. It has increased from 15.67 (Mar 24) to 17.85, marking an increase of 2.18.
- For Return On Assets (%), as of Mar 25, the value is 7.31. This value is within the healthy range. It has increased from 7.07 (Mar 24) to 7.31, marking an increase of 0.24.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.28. This value is within the healthy range. It has decreased from 0.30 (Mar 24) to 0.28, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.92. This value is within the healthy range. It has decreased from 0.96 (Mar 24) to 0.92, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.79. It has decreased from 0.86 (Mar 24) to 0.79, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 1.5. It has decreased from 1.36 (Mar 24) to 1.28, marking a decrease of 0.08.
- For Quick Ratio (X), as of Mar 25, the value is 0.63. This value is below the healthy minimum of 1. It has decreased from 0.74 (Mar 24) to 0.63, marking a decrease of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.37. This value is below the healthy minimum of 4. It has increased from 2.38 (Mar 24) to 3.37, marking an increase of 0.99.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 8.60. This value is below the healthy minimum of 20. It has decreased from 26.59 (Mar 24) to 8.60, marking a decrease of 17.99.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.53. This value is below the healthy minimum of 20. It has decreased from 19.12 (Mar 24) to 6.53, marking a decrease of 12.59.
- For Earning Retention Ratio (%), as of Mar 25, the value is 91.40. This value exceeds the healthy maximum of 70. It has increased from 73.41 (Mar 24) to 91.40, marking an increase of 17.99.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.47. This value exceeds the healthy maximum of 70. It has increased from 80.88 (Mar 24) to 93.47, marking an increase of 12.59.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.99. This value is within the healthy range. It has decreased from 5.81 (Mar 24) to 4.99, marking a decrease of 0.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.75. This value is within the healthy range. It has decreased from 4.22 (Mar 24) to 3.75, marking a decrease of 0.47.
- For Enterprise Value (Cr.), as of Mar 25, the value is 9,123.03. It has decreased from 9,248.47 (Mar 24) to 9,123.03, marking a decrease of 125.44.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.94. This value is within the healthy range. It has decreased from 3.49 (Mar 24) to 2.94, marking a decrease of 0.55.
- For EV / EBITDA (X), as of Mar 25, the value is 16.19. This value exceeds the healthy maximum of 15. It has decreased from 20.48 (Mar 24) to 16.19, marking a decrease of 4.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.39. This value is within the healthy range. It has decreased from 2.94 (Mar 24) to 2.39, marking a decrease of 0.55.
- For Retention Ratios (%), as of Mar 25, the value is 91.39. This value exceeds the healthy maximum of 70. It has increased from 73.40 (Mar 24) to 91.39, marking an increase of 17.99.
- For Price / BV (X), as of Mar 25, the value is 3.77. This value exceeds the healthy maximum of 3. It has decreased from 4.66 (Mar 24) to 3.77, marking a decrease of 0.89.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.39. This value is within the healthy range. It has decreased from 2.94 (Mar 24) to 2.39, marking a decrease of 0.55.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in CCL Products (India) Ltd:
- Net Profit Margin: 9.99%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.85% (Industry Average ROCE: 7.88%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.77% (Industry Average ROE: 16.74%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.75
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.63
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.4 (Industry average Stock P/E: 65.9)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.92
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.99%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Plantations - Tea & Coffee | Duggirala, Guntur District Andhra Pradesh 522330 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Challa Rajendra Prasad | Executive Chairman |
| Mr. Challa Srishant | Managing Director |
| Mr. B Mohan Krishna | Executive Director |
| Ms. Challa Shantha Prasad | Non Executive Director |
| Mr. Satyavada Venkata Ramachandra Rao | Non Executive Director |
| Mr. K V Chowdary | Independent Director |
| Mr. Durga Prasad Kode | Independent Director |
| Mrs. Kulsoom Noor Saifullah | Independent Director |
| Dr. Krishnanand Lanka | Independent Director |
| Mr. Sudhakar Ambati | Independent Director |
FAQ
What is the intrinsic value of CCL Products (India) Ltd?
CCL Products (India) Ltd's intrinsic value (as of 21 January 2026) is ₹881.61 which is 6.71% lower the current market price of ₹945.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹12,642 Cr. market cap, FY2025-2026 high/low of ₹1,074/475, reserves of ₹2,060 Cr, and liabilities of ₹4,288 Cr.
What is the Market Cap of CCL Products (India) Ltd?
The Market Cap of CCL Products (India) Ltd is 12,642 Cr..
What is the current Stock Price of CCL Products (India) Ltd as on 21 January 2026?
The current stock price of CCL Products (India) Ltd as on 21 January 2026 is ₹945.
What is the High / Low of CCL Products (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of CCL Products (India) Ltd stocks is ₹1,074/475.
What is the Stock P/E of CCL Products (India) Ltd?
The Stock P/E of CCL Products (India) Ltd is 37.4.
What is the Book Value of CCL Products (India) Ltd?
The Book Value of CCL Products (India) Ltd is 156.
What is the Dividend Yield of CCL Products (India) Ltd?
The Dividend Yield of CCL Products (India) Ltd is 0.53 %.
What is the ROCE of CCL Products (India) Ltd?
The ROCE of CCL Products (India) Ltd is 13.1 %.
What is the ROE of CCL Products (India) Ltd?
The ROE of CCL Products (India) Ltd is 17.0 %.
What is the Face Value of CCL Products (India) Ltd?
The Face Value of CCL Products (India) Ltd is 2.00.